arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

ClearPoint Neuro, Inc.

CLPT
$8.68 ▼ -1.48 (-14.62%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
66 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

ClearPoint Neuro, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $268.9M
Dividend Yield —
Revenue Growth 36.3% ↗
Op. Margin -52.4% ↗
ROIC -8.1% ↗
FCF / Share $-0.65 ↘
Trailing P/E —
Price / Book 10.2x
FCF Yield —
Debt / Equity 1.86
info Valuation on last close. End-of-day price, Nov 5, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.07M
↑ +36.3% —
Net Income Profit after all expenses
$-9.55M
↓ -58.5% —
Operating Margin Operating profit as % of sales
-52.4%
↑ +44.3% 4th
FCF / Share Free cash flow per share
$-0.65
↓ -172.6% —
Long-Term Debt Long-term obligations
$50.84M
↑ +1.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
4
Returns ↓
10
Financial Health →
18
Cash Quality ↑
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 66 quarters